Terms ending in 2040
Every in-force patent on Sandoz AG's record whose computed term ends in 2040, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US D1,057,937 | Drug Delivery Device In force · High confidence | Sandoz AG | In force | High confidence | |
| US D1,067,421 | Inhaler In force · High confidence | Sandoz AG | In force | High confidence | |
| US D1,083,620 | Packaging In force · High confidence | Sandoz AG | In force | High confidence | |
| US D1,087,326 | Drug Delivery Device In force · High confidence | Sandoz AG | In force | High confidence | |
| US D1,088,218 | Drug Delivery Device In force · High confidence | Sandoz AG | In force | High confidence | |
| US D1,092,724 | Medical Autoinjector Device In force · High confidence | Novartis Pharma AG | In force | High confidence |
6 of 6 patents shown. Soonest term end first, then patent number.
5 of these are in force and held by Sandoz AG.
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.